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Abstract Today’s treatment and diagnosis of prostate
cancer still exhibit major limitations. The search for new
and additional prognostic markers is therefore still an actual
Weld of interest. Potential markers involved in numerous
biological processes in the tumor cell have been investi-
gated intensively. For therapeutic interventions it is impor-
tant to distinguish between harmless and aggressive disease
in an early stage. Therefore the subject of this review is
limited to markers associated with those functional pro-
cesses, which discriminate early stage aggressive, meta-
static cancer from harmless disease. Important processes in
this respect are: altered cell adhesion and cellular migra-
tion. E-cadherin, N-cadherin, -catenin, integrins, focal
adhesion kinase, connexins and matrix metalloproteinases
all appear promising biological markers associated with the
early stage metastatic process in prostate cancer. Here we
discuss their potential to become valid biological markers
based on literature data. Thus far, none of these markers
proved to be a valid individual marker by itself due to
prostate cancer heterogeneity and transient expression.
Analyzing a combination of the potential markers discussed
in this review is expected to be a better approach toward
discriminating high- from low-risk tumors in an early stage
of prostate cancer.
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Introduction
Prostate cancer (PC) is the most frequent cancer in men of
western countries (Crawford 2003). Screening for prostate
speciWc antigen (PSA) in asymptomatic populations has
increased the detection rate of prostate cancer as well as the
number of surgical and radiotherapeutic treatments.
Recently, the use of PSA as a diagnostic marker has come
to be discussed (Stamey et al. 2002). An elevated level of
serum PSA not only detects aggressive malignancy but it is
also associated with benign prostate hyperplasia (BPH) and
with mildly aggressive, slowly progressing, neoplasia. Fur-
thermore, aggressive and metastatic prostate tumors have
been identiWed which showed no elevated serum level of
PSA. In addition, approximately 86% of men diagnosed
with PC are not destined to die from the disease (Klotz
2006).
A large proportion of prostate carcinomas remain con-
Wned in the prostate, while only a small proportion of carci-
nomas acquire the ability to metastasize. Pathological
grading using the Gleason score, together with PSA mea-
surement is still insuYcient to distinguish between indolent
tumors and aggressive metastatic tumors. Gleason score is
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for prostate carcinoma. More aggressive disease is associ-
ated with higher Gleason scores. The Gleason score is a
summation of the two most prevalent Gleason grades
(1–5). This reXects tumor heterogeneity often present in
prostate cancer. Subpopulations of tumor cells within the
tumor, therefore, should be identiWed in an early phase of
disease management enabling adequate prediction of tumor
behavior.
Low-grade tumors, as deWned by pathological examina-
tion of biopsies, are usually left untreated. A watchful wait-
ing approach may be adopted till progressing carcinoma is
suspected. Based on serum PSA level, number of tumor-
containing core-biopsies and Gleason score of the tumor,
patients may be selected for a wait and see approach.
Rising PSA levels, PSA doubling time and local tumor
growth are indicators that a tumor is progressing. At pres-
ent, adequate prognostic or predictive markers for tumor
progression are still lacking. Although PSA combined with
pathological grading is still considered as the most reliable
diagnostic marker today, the number of false positives and,
therefore, unnecessary treatments indicate a need for new,
or additional, prognostic markers, which are able to distin-
guish between indolent and aggressive prostate carcinomas
at an early stage. Here we select potential markers that may
be used to distinguish between indolent and aggressive
tumors at an early stage, based on biological function and
expression in prostate carcinoma.
Marker selection criteria
Early stage
A suitable marker should distinguish normal tissue from
carcinoma. Prostate cancer usually occurs in elderly men.
Low aggressive carcinomas do not always need treatment
while patients often die from other factors than the prostate
cancer itself. So, in addition, it would be optimal if the
marker were able to diVerentiate between low and high
aggressive carcinomas. As treatment is most successful at
early stages of the disease, a prognostic marker should dis-
tinguish between low- and high aggressive carcinoma as
early as possible.
Biological processes involved in metastasis 
Early stage disease diVers from later stages in tumor volume,
localization and metastatic potential. The Wrst diVerence
between high and low aggressive carcinomas is its potential
to metastasize. Therefore, an early discrimination could be
made on the base of the biological processes at work in the
epithelial cells, which lead to metastatic potential.
Other biological processes involved in tumor progres-
sion are less likely to distinguish high- from low aggressive
disease in an early stage. For example; cell proliferation is
disturbed in both low grade and early-stage diseases; this
process is not likely to involve a protein, which could dis-
tinguish high- from low aggressive carcinomas. Further-
more, processes involved in later stage diseases, like
developing androgen independency as a consequence of
androgen depletion therapy, homing of metastatic cells in
lymphatic or bone tissue and neoangiogenesis cannot be
detected in early stage disease. Proteins involved mainly in
those processes are therefore not likely to be adequate
markers in early stage disease and will not be subject of this
review. Here potential markers are discussed based on their
biological function in the early metastatic process as this
may reXect future tumor behavior in early stage disease.
Change in expression
Although biological function is important, a molecule’s
role in tumorigenesis is not a license to become a valid
marker. A change in expression, or expression pattern, may
be suYcient to detect malignancy. However, an optimal
marker must be representative for disease progression. This
means that the expression of the candidate marker must be
proportional to, or inversely related to, disease progression.
Most convincing would be a marker, which is overexpres-
sed in tissues developing into aggressive carcinoma. As it
would be optimal to distinguish aggressive carcinoma from
indolent disease as early as possible, a change in expression
compared to normal tissue must be observable in an early
stage of disease.
Prostate cancer metastasis
The complex mechanism of metastasis and its regulation in
human carcinomas is only beginning to be understood. For
successful dissemination and metastatic growth a tumor
cell needs to overcome several obstacles. The cell has to
detach from the local primary tumor tissue architecture and,
subsequently, invade the surrounding tissue, leading to
invasive growth. Motile cells then have to enter the blood-
stream, to intravasate, and travel in the vascular network to
reach a distant location. Then the cell must be able to leave
the bloodstream and invade into the target tissue and prolif-
erate at the target site. Homing of the tumor cells at distant
tissues is mainly regulated by the microenvironment of the
target tissues. The production of growth factors and chemo-
kines of distant tissues in combination with the expression
of cell surface receptors on the tumor cell could result in the
tumor cell’s extravasation and ultimate settlement and pro-
liferation in the target tissue. During the processes of123
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be able to survive independently outside of its normal
environment.
The Wrst step in metastasis is the detachment of the cells
from the primary tumor and the gain of motility of those
cells occurring between stage 1 and 2 (Fig. 1). As this is
one of the Wrst occurring diVerences between localized
tumor cells and cells that gain metastatic potential, this pro-
cess is a start to distinguish indolent tumors from their
aggressive counterparts.
Primary migration
The epithelial cells adapt a migratory phenotype during the
process of metastasis. The migration of epithelial cells is
also involved in several organ genetic and morphogenetic
processes during embryonic development. This migration,
which is strictly regulated, shows parallels with the meta-
static process of carcinomas (Grunert et al. 2003; Huber
et al. 2005). One of the possible mechanisms of primary
migration in embryonic development is proposed as the
‘epithelial to mesenchymal transition’ (EMT) of epithelial
cells (Thiery 2002). In EMT epithelial cells shift from a
rigid and steady phenotype to a highly motile phenotype,
and as such, EMT merely is new nomenclature for one of
the key steps in the invasive process. One of the character-
istics of EMT in embryonic development is the loss of
expression of cell adhesion molecules, Wlament assembly
and the expression of extra cellular proteins like Wbronectin
and/or collagen (Boyer et al. 2000). However, the exact
nature and regulation of a similar transition in carcinomas
has not yet been fully elucidated.
Although a process like EMT may be involved during
the Wrst stages of carcinoma metastasis, this process is not
the only possible mechanism of action. Another mechanism
of carcinoma cell motility is a process called collective
motility. In this process of invasion a collection of cells are
moving from the primary tumor without individual de-
attachment of the cells (Sahai 2005). The search for mark-
ers is not limited to one single process, as it is yet un-identi-
Wed by which process prostate carcinoma cells are gaining
invasive properties. Markers for EMT alone are not suY-
cient to detect all cells with invasive properties, as EMT
may not be the only process involved. A combination of
markers involved in distinctive processes seems to be a
more promising approach.
In general, the primary migration of carcinoma cells is
divided into three diVerent events; loss of cell–cell adhe-
sion, (partial) degradation of the extra cellular matrix
(ECM) and actin/cytoskeletal changes within the cell. Dur-
ing an EMT-like mechanism all these processes occur
while during collective motility the loss of cell–cell adhe-
sion only takes place at speciWc sites. This occurs likely at
the leading edge of the motile complex of cells, rather than
on each individual cell. Detecting the loss of certain adhe-
sion molecules or the gain of molecules corresponding to
cell-motility is therefore not straightforward. A combina-
tion of markers involved in these processes may give
insight into the complex mechanism of invasion. Further-
more, expression changes of these markers may reXect the
tumors metastatic potential. An overview of those markers
is given in Table 1.
Cell adhesion
The epithelial cells of the prostate are categorized into three
types; the basal cells, the luminal epithelial cells and the
secretory cells. The basal epithelial cells are the Wrst to
appear during normal human prostate development. These
cells subsequently undergo diVerentiation into intermediate
and secretory cells. The epithelial cells however, become
less diVerentiated during prostate carcinoma progression.
Cells appear with features of both basal and luminal cells
(Knudsen and Miranti 2006). The epithelial cells in the
prostate gland are bound to one another as well as to the
extracellular matrix (ECM). In the normal human prostate,
Fig. 1 DiVerent stages of tumor metastasis presented in a schematical
way. Stage 1 the primary tumor. There are no signs of migratory action.
Stage 2 invasive growth. Cells de-attach from the primary tumor and
start to invade the surrounding tissue. Stage 3 intravasation. Migratory
cells reach the nearest blood vessel and intravasate into the blood
stream. Stage 4 extravasation. Traveling cells escape from the vessel
and start to invade secondary tissues and micrometastasis of single
surviving cells develops. Stage 5 macrometastasis. Micrometastasis
progresses to macrometastasis, a secondary tumor has developed
(adapted from Huber et al. 2005)123
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ing to the substratum. However, less diVerentiated cells
inWltrate into the basal cell layer in invasive carcinoma,
indicating a change in cell adhesion.
Cell–cell adhesion is mediated by diVerent junction pro-
tein complexes, while binding to the ECM is mainly regu-
lated by integrins. The loss of cell–cell adhesion together
with the gain of cell–ECM interactions, either transient or
permanent, is an indispensable process when the carcinoma
progresses to an invasive state (Stewart et al. 2004). Pro-
teins involved in altered cellular adhesion properties may,
therefore, function as biological markers.
Cell–cell adhesion
Cell–cell adhesion is mediated by adherens and tight junc-
tions between epithelial cells. During the metastatic process
of epithelial cells, both the composition of these cell junc-
tions and the number of junctions change. Cell adhesion
molecules (CAMs), like E-cadherin and N-cadherin as well
as -catenin, are proteins, which are structurally involved
in those junctions.
E-cadherin
E-cadherin, which is a member of the cadherin family of
CAMs, mediates lateral cell–cell adhesion in secretory tis-
sues, like the prostate. E-cadherin is a type-1 Ca2+-depen-
dent cell adhesion molecule and is a major component of
adherens junctions in epithelial cells. E-cadherin is located
at the cell membrane. It facilitates the binding to diVerent
catenins (-, - and -catenin) that associate with actin Wla-
ments and the actin cytoskeleton within the cell.
The expression of E-cadherin has been extensively stud-
ied using tissue micro array (TMA) in prostate tumor,
derived from radical prostatectomy (RP) (Rubin et al.
2001). In low-grade carcinomas with negative surgical mar-
gin, benign and normal tissue E-cadherin was normally
expressed. The expression of E-cadherin was decreased in
higher grade carcinomas and carcinomas with a positive
surgical margin. Furthermore, metastatic tissues showed
strong E-cadherin staining. This is rather controversial,
as the related primary tumors showed loss of E-cadherin
expression. The re-expression of E-cadherin in metastasis
may imply that the loss of E-cadherin is a transient
event occurring during invasion and diapedesis. The re-
expression of E-cadherin in metastatic tissue may be regu-
lated  by paracrine signaling from cells of the metastatic
environment.
The low expression of E-cadherin has been correlated
with prostate speciWc antigen recurrence in serum after RP,
suggesting that aberrant E-cadherin expression could be
predictive of clinical outcome (Rhodes et al. 2003). The
expression of E-cadherin is inversely correlated to tumor
grade, even within one RP specimen containing both
benign and malignant tissues (Jaggi et al. 2005). This also
underlines the diYculty of E-cadherin expression analysis
using prostate biopsies compared to PC specimens. Most
Table 1 Potential markers involved in the early metastatic processes of prostate cancer
Shown are the biological processes in which the markers are involved, the name of the markers, the change in expression, and the tissues in which
the Wrst signiWcant change in expression of the marker was observed and references
ECM Extracellular matrix, PIN prostatic intraepithelial neoplasia, PC prostate carcinoma, FAK focal adhesion kinase, CX connexin, MMP Matrix
metalloproteinase
Biological process Marker Expression 




Cell–cell adhesion E-cadherin # PC: Gleason Score 7–10 Rubin et al. (2001), 
Jaggi et al. ( 2005), 
Rhodes et al. ( 2003)
N-cadherin " PC: Gleason Score 7–10 Jaggi et al. (2006)
Membranous -catenin # PIN Horvath et al. (2005) 
Jaggi et al. (2005)
Wnt Signaling Nuclear -catenin " PC: Gleason Score 4–10 Horvath et al. (2005)
Cell–ECM Adhesion 4-integrin # PIN Davis et al. (2001)
Integrin signaling/cell motility FAK " PIN Rovin et al. (2002)
Intercellular 
signaling/cell–cell adhesion 
CX26 " PC: Gleason Score 6 (3+3) Tate et al. (2006)
CX43 # PC: Gleason Score 5–10 Habermann et al.(2002)
CX32 # PC: Gleason Score 5–10 Habermann et al. (2002)
ECM Degradation MMP-2 " PC: Gleason Score >5 Trudel et al. (2003); 
Wood et al. ( 1997)
MMP-9 " PC: Gleason Score >5 Trudel et al.(2003) 
Wood et al.(1997)123
J Cancer Res Clin Oncol (2007) 133:687–695 691prostate tumors are multi-focal and heterogeneous. During
sampling of prostate biopsies, foci of malignant carcinoma
within the prostate could be missed.
Most studies used a large number of samples (ranging
from 16 to 259) to analyze the correlation of E-cadherin
expression and tumor grade. Although a diVerence could be
seen between the two groups of samples (high- vs. low
Gleason score), not all individual cases showed a low
E-cadherin expression in combination with a high Gleason
score, indicating that E-cadherin expression may not be
used as an individual marker. However, we may use
E-cadherin expression data in combination with other
markers of metastasis.
Besides decreased expression of E-cadherin, various
studies were directed to the role of E-cadherin gene
(CDH1) polymorphisms (Bonilla et al. 2006; Li et al. 2006;
Verhage et al. 2002). A -160 C/A single nucleotide poly-
morphism was found in allele A. (Liet al. 2006). This
polymorphism showed approximately 70% decreased tran-
scription of allele A. This may be a cause of the decreased
E-cadherin expression as observed in prostate carcinoma.
The suitability of this polymorphism in predicting prostate
carcinoma metastasis is, however, controversial. An
elevated risk for prostate carcinoma was observed in allele
A carriers in a Dutch population, with a higher risk for spo-
radic cancers (approximately Wvefold) compared to heredi-
tary cancer (approximately twofold) (Verhage et al. 2002).
This is contradictory to Swedish results, which showed a
higher risk for hereditary cancers (Jonsson et al. 2004).
More CDH1 polymorphisms were studied in African-
Americans, Jamaicans and European-American men
(Bonilla et al. 2006). This study showed that a combination
of polymorphisms (160A and +54T) might present a sus-
ceptibility for prostate cancer in European populations.
The discrepancy between results of various studies
reveals that more research must be done to link CDH1
polymorphisms to metastatic disease in prostate cancer. It
is suggested that polymorphisms decrease E-cadherin tran-
scription and thereby its expression. Therefore, E-cadherin
protein expression itself, instead of gene polymorphisms,
may be a valid marker. It could be even more promising to
use E-cadherin protein expression data in combination with
other markers.
N-cadherin
N-cadherin is just like E-cadherin a type-I cadherin. While
E-cadherin is mostly expressed in epithelial cells, N-cadh-
erin is expressed in various cell types including nerve,
myocardial and mesenchymal cells. Increase in N-cadherin
expression is one of the features of epithelial to mesenchy-
mal transition (EMT), together with loss of E-cadherin
expression. The expression of E-cadherin declines, while
N-cadherin expression increases during the process of
EMT. N-cadherin facilitates a more dynamic cell–cell
adhesion. N-cadherin expression in prostate cancer is less
well studied compared to E-cadherin expression. In one
study, the switch of cadherin expression was associated
with higher grade tumors (Jaggi et al. 2006). In a total of 44
PC specimens 45% showed N-cadherin expression. Only
7% of the Gleason 5–6 tumors showed positive expression,
compared to 65% of Gleason grade 7, and 57% of Gleason
score 8–10. Although N-cadherin expression correlates
with Gleason score, no data are available correlating N-
cadherin expression to PSA recurrence, metastasis or tumor
progression.
-catenin
-Catenin is a multifunctional protein; it is not only involved
structurally in the adherens junction complex, but it also acts
as signaling molecule. It connects the cytoplasmic part of
E-cadherin to the cytoskeleton together with  catenin in the
adherens junctions. When adherens junction complexes are
lost, a soluble form of -catenin becomes localized in the
cytoplasm and some free -catenin is transported to the
nucleus. The cytoplasmic expression of -catenin is rather
low in normal cells as it is easily targeted for ubiquitination
by GSK-3 phosphorylation and subsequently degraded by
proteosomes. However, signaling by the Wnt pathway
represses the degradation of -catenin by degrading the
GSK-3/-catenin complex. This leads to suppressed phos-
phorylation of -catenin and, consequently, accumulation of
the protein. The Wnt signaling might be involved in prostate
cancer development (Yardy and Brewster 2005). Besides the
Wnt signaling pathway the Pi-3K/Akt pathway also seems to
be involved in regulating the soluble pool of free -catenin.
The Pi-3K/Akt pathway signaling is also involved in the
development of prostate carcinoma, mainly by loss of the
PTEN Akt suppressor (Downward 2004).
The higher levels of soluble -catenin may lead to higher
amounts of this protein in the nucleus were it exerts its tran-
scriptional function. It interacts with diVerent DNA-binding
transcription factors and especially the TCF/lymphoid
enhancer factor (LEF) family, which includes TCF1,
TCF3–4 and LEF1. Those DNA-binding proteins repress
the transcription of target genes by binding transcriptional
repressors. -catenin competes for binding with those
repressors, leading to transcriptional activation of the target
genes. The transcriptional activation of -catenin (CRT) is
involved in numerous processes in normal cells, from
embryonic anterior–posterior axis speciWcation to tissue
development. Hyper-activation of CRT signaling may elicit
pronounced morphology and trans-diVerentiation in
prostatic neoplasia (Chesire et al. 2002). Although the loss
of adherens junctions leads to accumulation of free soluble123
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of -catenin signaling as free -catenin is rapidly degraded.
However, in combination with ubiquitination repression,
-catenin accumulation could be, partially, responsible for
prostate carcinoma progression due to elevated CRT signal-
ing.
Normal prostate tissue shows high membranous -cate-
nin expression and low nuclear -catenin staining. Prostatic
intraepithelial neoplasia (PIN) lesions show less expression
of membranous -catenin. This indicates that the loss of
adherens junctions is an event occurring early in tumor
development, assuming PIN lesions as precursors of pros-
tate carcinoma.(Jaggi et al. 2005) However, the loss of
membranous -catenin occurs at a very low rate and does
not correlate with tumor stage or grade. The loss of mem-
branous -catenin could be a direct consequence of loss of
adherens junctions early in tumor development.
Membranous -catenin was lowered in both benign
prostate hyperplasia (BPH), a non-malignant enlargement
of the prostate, and localized prostate cancer (Horvath et al.
2005). Nuclear -catenin staining is stronger in BPH com-
pared to normal prostate tissue. This indicates that -cate-
nin accumulation in the cytoplasm, due to loss of
membranous -catenin, leads to higher nuclear levels.
However, when compared with localized prostate cancer,
BPH had higher levels of nuclear staining. Advanced pros-
tate cancer showed even less nuclear -catenin staining
compared with localized disease. Furthermore, lower levels
of nuclear -catenin correlate with poorer prognosis (Horv-
ath et al. 2005).
-catenin signaling may both, repress and promote
tumor growth. Higher nuclear -catenin levels indicate
tumor repression while lower nuclear -catenin levels indi-
cate tumor growth. The stabilization of nuclear -catenin
levels is regulated by various cofactors and the balance
between those factors and -catenin results in tumor pro-
motion, or repression. The fact that relatively low nuclear
-catenin levels do correlate with disease outcome suggests
nuclear -catenin as a possible marker. More studies of
low-risk prostate cancer may clarify the role of nuclear
-catenin levels during prostate cancer progression.
Cell-ECM adhesion/focal adhesions
Besides cell–cell adhesion, epithelial cells are also con-
nected to the ECM. The interaction with the ECM is indis-
pensable for the traveling of a metastatic cell. The
interaction with the ECM changes when the cell has meta-
static potential. Integrins may be involved in such changes.
Integrins are important mediators in the attachment of
epithelial cells to the ECM. These appear in complexes at
the cell surface known as focal adhesions. Integrins play an
important role in tumor-associated signaling events besides
anchoring to the ECM. Focal adhesion kinase (FAK) is an
important mediator of integrin signaling. Integrin-depen-
dent signaling is supposed to aVect cell growth, anchorage-
dependent diVerentiation, adhesion, motility and apoptosis.
Integrins
Integrins appear in heterodimeric structures containing an 
and  chain. The predominant structures found on epithelial
cells are the 51, 61 and the 64 integrins. The supra-
basal and secretory cells are distinct from the basal cells in
the expression of integrins and adhesion molecules that are
able to connect to the substratum. In normal prostate
glands, only the basal cells express integrins connecting
them to the substratum. The 64 integrin, for example, is
an important component of the hemidesmosome expressed
at the basal surface in most stratiWed epithelial cells. The
hemidesmosome links the cytoskeleton intermediate Wla-
ments to laminin-5 in the ECM.
Basal epithelial cells are lost during PC progression. Par-
tial loss of the basal lamina is a hallmark of high-grade
PIN. The basal cell lining almost completely disappears in
PC. The expression of integrins changes together with the
loss of the basal lining. The 4 integrin, for example, was
lost in PIN lesions together with basal cell-lining and in
prostate carcinoma the expression of 4 integrins was
totally lost (Davis et al. 2001). Although the 4 integrin
was lost, the 61 integrin showed to be continuously
expressed through all cancer stages, which may indicate
that the composition of integrins changes during tumor
progression.
Expression of laminin-5, the major ligand of 64 inte-
grin, is also declining through PC progression (Davis et al.
2001). This may indicate that the composition of the local
ECM is rather important for physiology. The continuous
expression of the 61 integrin together with the loss of
64 integrin may reXect the motility of the cancer cells.
Loss of the 64 integrin may give a less-stable attachment
to the ECM, while the continued expression of the 61
integrin may provide enough attachment for the cells to
become mobile. This may also explain why prostate cancer
cells favor to move along laminin-5 coated nerves (Cress
et al. 1995).
The composition of integrins in prostate cancer tissue,
like the combination of loss of 64 and continuous expres-
sion of 61, may reXect the capability of the cells to
metastasize. Such a combination may, therefore, be a valid
biological marker.
Focal adhesion kinase
Signaling of integrins is mediated by the connection of
integrins to focal adhesion kinase (FAK). FAK, a protein123
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membrane and signals through the phosphoidyllinositol 3
kinase (PI 3) pathway. This integrin-dependent signaling is,
in general, known to regulate several tumor-progressing
processes as cell growth, adhesion-based diVerentiation,
adhesion, motility and apoptosis (Downward 2004).
Increasing levels of FAK in human prostate cancer cell
lines correlate with greater metastatic potential (Tremblay
et al. 1996). FAK was predominantly expressed in the basal
epithelial cell layer as shown in an immunohistochemical
analysis of various prostate specimens (Rovin et al. 2002).
FAK overexpression appeared in PIN lesions, with a clear
distribution of high FAK staining in neoplastic cells while
normal cells in the surrounding normal tissues did not show
elevated expression. Furthermore, benign prostate hyper-
plasia (BPH) did not show a change in FAK expression
compared to normal tissue. Beside the FAK overexpression
in PIN lesions, higher grade and metastatic carcinomas
retained the elevated FAK expression, suggesting an impor-
tant role for FAK in tumor progression (Rovinet al. 2002).
The elevated expression of FAK in early stage carcinoma
may, therefore, be used as a biological marker.
Gap junctions and gap junctional intercellular 
communication (GJIC)
Comparing tight and adherens junctions with gap junctions,
the latter is used for intercellular communication rather
than anchoring to neighboring cells. Gap junctions are
intra-cellular membrane channels composed of a pair of
hemi-channels (connexons), which are formed by oligo-
merization of six protein sub-units, which are called con-
nexins. The connexons align to the connexons of an
adjacent cell creating an intracellular channel. These chan-
nels are able to transport ions and small molecules
(<1.5 kDa) between cells. This intercellular communication
is termed gap junctional intercellular communication
(GJIC), and is involved in tissue homeostasis, growth con-
trol, diVerentiation and apoptotic events. Gap junction for-
mation has been reported to decrease as cancer progresses.
As connexins are the major components of the gap junc-
tions, a change in connexin expression may serve as indica-
tor for cancer progression.
Connexins
Of the existing connexins only CX43 and CX32 and CX26
are known to be expressed in endocrine and exocrine
glands. In normal prostate tissues CX32 is punctually
expressed in the luminal cells on cell borders but also
diVuse in the cytoplasm. CX43 is punctually expressed
mainly in the basal cell compartment on cell borders. As
most of the epithelial cells in the prostate glands are lumi-
nal cells, detecting CX43 is diYcult.
CX43 and CX32 have been studied in prostate tissues. In
normal tissue and BPH both connexins were expressed.
However, in some of the samples only one of the connexins
was expressed. Not even one tissue specimen was negative
for both connexins. BPH tissue showed stronger connexin-
staining compared with normal tissue. In prostate carci-
noma tissue the expression of connexins was less compared
with BPH and normal tissue. In addition, some samples
showed loss of both connexins (Habermann et al. 2002).
In a study of prostate cancer cell line (LNCaP and PC-3)
progression models it was found that CX26 and CX43 were
overexpressed (Tate et al. 2006). This Wnding conXicts with
previous clinical Wndings (Mesnil 2002). However, the
overexpression of CX26 was conWrmed by immunohisto-
chemical analysis of clinical specimens. In samples with a
high Gleason score (3 + 3) 66% stained moderately to
intensively for CX26. In benign tissues, only 29% had a
similar expression (Tate et al. 2006). This overexpression
seems to be unrelated to the gap junction formation, as
CX26 was not localized to gap junction structures in inves-
tigated cell-line models. Furthermore, immunoprecipitation
showed that CX26 complexes with focal adhesion kinase
(FAK). FAK is a kinase, which interacts with activated
integrins and aVects the cytoskeleton to improve motility,
discussed earlier in this review.
The role of connexins in tumorigenesis is still largely
unknown; however, the aberrant expression of connexins
may indicate that the loss of GJIC is involved in the patho-
genesis of prostate cancer. Furthermore, the overexpression
of CX26 and its interaction with focal adhesion kinase sug-
gests that connexins could be involved in tumor progres-
sion, independent of gap junction formation. So the
individual gain of connexin expression may be a valid
marker for tumor progression.
Extracellular matrix (ECM) degradation
A cell has to travel through the extracellular matrix (ECM)
as soon as it becomes invasive. The ECM must be partially
degraded to allow the cells’ passing. Matrix metalloprotein-
ases (MMPs) are the only known enzymes, which are able
to degrade the ECM as well as the basement membrane and
so they are thought to be important mediators during tumor
metastasis.
Matrix metalloproteinase (MMPs)
The matrix metalloproteinases are endopeptidases, which
include approximately 20 zinc-dependent proteinases that
degrade several components of the ECM like collagen,123
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MMPs the type IV collagenases are thought to be involved
in prostate-cancer invasion. Type IV collagenases are able
to degrade collagen, thereby facilitating the penetration of
the basement membrane. MMP2 and MMP9 are both exten-
sively studied. Overexpression of both MMP2 and MMP9
is correlated with a higher Gleason score and invasive
phenotypes (Wood et al. 1997). Furthermore, overexpression
of MMP2 is negatively correlated with disease-free sur-
vival(Trudel et al. 2003).
MMPs are mainly produced by stromal cells. The pro-
duced MMPs occur in their inactive form and become acti-
vated by other MMPs. For example, MMP2 is produced as
the inactive pro-MMP-2. This soluble form is cleaved by
MMP14 to produce the active MMP-2. The active forms of
MMP-2 and MMP-13 in their turn are able to activate
MMP-9. This active form is able to bind to the integrins
outside of the cancer epithelial cells to perform its function.
This also implicates diYculties in measuring expression of
the active MMPs. Only the bound MMPs form must be
taken in account, which means that a good distinguishing
must be made between normal versus malignant cells
within the tissue sample.
Both MMP-2 and MMP-9 overexpression is implicated
as prognostic marker in prostate cancer, together with
downregulation of their inhibitors; the tissue inhibitors of
metalloproteinases (TIMPs) (Morgia et al. 2005). Further-
more, the mRNA ratio between MMP9 and E-cadherin
showed to be an important indicator for clinical outcome
after radical prostatectomy(Kuniyasu et al. 2003). This
implies that the expression of metalloproteinases could be
used as biological marker in combination with other mark-
ers involved in the metastatic process.
Multiple marker approach
The search for new prognostic markers in prostate cancer is
increasingly becoming a Weld of interest since the last
decade. Most researchers aimed at Wnding one single marker.
They focused on the diVerence in expression between patient
groups with low-aggressive carcinomas versus groups with
high-aggressive carcinomas. Such a strategy revealed a sig-
niWcant correlation between a change in expression of the
single marker and disease development in a number of stud-
ies. However, this correlation merely indicates a role of the
discussed marker in tumor development; it does not indicate
the actual disease process in an individual patient.
In view of the complexity of the prostate tumor pathol-
ogy the success of searching for one single marker seems
very small. Tumors of the prostate are heterogeneous, not
only presenting multiple tumor foci but also a heterogeneous
appearance within one single tumor. For a prostate tumor to
become metastatic and dangerous, multiple mechanisms
must be activated: from loss of cell adhesion to increasing
cell motility as well as a change in the direct tumor environ-
ment. Not all of these mechanisms appear at the same time
and some processes are even transient. Focusing on one
single marker may therefore not be suYcient. To study a
cohort of markers representing multiple biological pro-
cesses may give a better indication for tumor progression
than one single marker could.
Concluding remarks
In this review potential markers, which represent essential
biological functions within the Wrst step of tumor progres-
sion were discussed: gaining metastatic potential. E-cadh-
erin, N-cadherin, -catenin, integrins, focal adhesion kinase
(FAK), connexins and metalloproteinases (MMPs) are
markers that represent cell–cell adhesion, cell–ECM inter-
action and ECM degradation.
Today, there is still little knowledge of the clinical value
of the discussed mechanisms. Creating a model of con-
certed expression of markers involved in those mechanisms
and analyzing their correlation with disease progression,
may provide more insight into the early biological pro-
cesses of metastasis and their clinical values. When expres-
sion analysis of markers in a cohort of tumor samples is
performed, a possible prediction scheme could be generated
for individual cases. In such an analysis not only the
expression of one single marker but rather the expression
ratio between multiple markers is expected to be of more
prognostic value.
A concerted expression model of a combination of mark-
ers, representing aggressiveness in early stage prostate can-
cer could have important clinical impact by providing a
more eYcient approach towards diagnosis and treatment of
early-stage prostate cancer.
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